<wonder who's gonna win......>
Maybe everyone....
I guess you could say I am partial to Agouron, and there's even more reason now, with Remune......
but at least it is not blind faith. I read a lot :- )
Now, wouldn't that be something, Remune…..and Immune Response, Institute of Human Virology and Robert Gallo, Agouron, Warner-Lambert….
This is in the WSJ Interactive,
Dow Jones Newswires -- May 10, 1999
Immune Response, Univ. Of Maryland In Licensing Pact
CARLSBAD, Calif. (Dow Jones)--Immune Response Corp. (IMNR) agreed to license rights for chemokine and hCG associated factor technology from the University of Maryland Biotechnology Institute.
In a press release Monday, the biopharmaceutical company said it will issue restricted stock to the institute as an initial license fee.
Chemokine and hCG were discovered by Dr. Robert Gallo and his associates at the Institute of Human Virology.
Immune Response will also sponsor a five-year renewable research program at the Institute of Human Virology and initiate a research effort of its own at the Biotechnology Institute facility.
Chemokines are biological regulators that are secreted by several types of cells in the body which appear to slow or block HIV infection and attract cells to the site of infection of inflammation.
HCG associated factor is a naturally occurring peptide which may have clinical applications in the direct treatment of cancer as an adjunct to chemo and/or radiation therapy by promoting bone marrow cell growth and differentiation and in HIV prevention and treatment, Immune Response said.
Immune Response said it will have the right to first refusal to license all new technology related to hCG associated factor and chemokines that is developed by the Institute of Human Virology, following the appropriate University of Maryland Biotechnology Institute policies. >>
-________________________
I think there is more to this collaboration than meets the eye, and country doctor's post at Yahoo, may be along the right lines.
messages.yahoo.com
There has been growing realization that the AIDS virus will probably never be completely eradicated from the body, but there is increasing hope that the HIV virus can be kept at bay or away, through the combined use of HAART and immune based therapies, with agents such as Remune.
The Remune data is eagerly anticipated by many. The DSMB postponed their review of the US Phase III trial to provide more time to obtain virological data. The Thai government is reviewing the Remune data. Gallo must be interested in Remune for this deal to have occurred.
Just a few kind of related studies:
[AEGiS] CDC HIV/STD/TB Prevention News Update 05/03/99
"Emergence of CTL Coincides With Clearance of Virus During
Primary Simian Immunodeficiency Virus Infection in Rhesus
Monkeys" Journal of Immunology Online (05/01/99) Vol.
162, No. 9, P. 5127; Kuroda, Marcelo J.; Schmitz, Jorn E.;
Charini, William A.; et al.
To determine the role of the CTL response in containing early
viral replication, researchers characterized the response during
primary SIV/macaque infection of rhesus monkeys using an
epitope-specific functional and an MHC class I/peptide
tetramer-binding assay. The researchers observed that the
percent of tetramer-binding CD8 T cells that was identified in
the animals' lymph nodes was lower than the percent identified in
PBL. The epitope-specific CD8 T cells expressed cell surface
molecules related to memory and activation. Based on their
findings, the researchers concluded that there is "strong
evidence for the importance of CTL in containing AIDS virus
replication."
and this study:
(UPI) Study: AIDS vaccine appears promising
Larry Schuster, UPI Science Editor
United Press International - Tuesday, April 27, 1999
aegis.com
WASHINGTON, April 26 (UPI)
Thanks for the data, Bill. guess it won't matter much in a few days.
|
